Paper Details
- Home
- Paper Details
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Author: BinderGary, BonizzoniErminio, Clark-SnowRebecca, NavariRudolph M, OlivariSilvia, RoelandEric J
Original Abstract of the Article :
<b>Aim:</b> In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (NEPA), a fixed neurokinin 1 RA (...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.2217/fon-2021-0023
データ提供：米国国立医学図書館（NLM）
Finding the Right Oasis for Chemotherapy-Induced Nausea and Vomiting
The desert of [cancer treatment] often comes with challenging side effects, and chemotherapy-induced nausea and vomiting (CINV) is one of the most common and debilitating. This study investigates the effectiveness of netupitant/palonosetron, a single-dose neurokinin 1 receptor antagonist (RA)/serotonin Type 3 (5-HT3) RA combination, compared to a 3-day regimen of aprepitant, another neurokinin 1 RA, for preventing CINV. The researchers pooled data from three clinical trials, demonstrating the effectiveness of netupitant/palonosetron in preventing both acute and delayed CINV compared to a 3-day aprepitant regimen. This study sheds light on the potential of netupitant/palonosetron as a more effective and convenient approach for preventing CINV in patients receiving chemotherapy.
A Single-Dose Solution for CINV Prevention
The study demonstrates that netupitant/palonosetron, given as a single dose on day 1, was more effective than a 3-day regimen of aprepitant in preventing delayed CINV. This finding is significant, as it potentially offers a more convenient and effective treatment option for patients struggling with this debilitating side effect of chemotherapy.
Navigating the Desert of CINV
This research is valuable for patients undergoing chemotherapy, providing new insights into the management of CINV. It highlights the potential benefits of netupitant/palonosetron in reducing the severity and duration of nausea and vomiting, potentially improving the patient's overall quality of life during treatment. As always, it's essential to discuss the potential benefits and risks of any medication with a healthcare professional to determine the most appropriate treatment approach for each individual.
Dr.Camel's Conclusion
This study is like a camel finding the perfect oasis in the desert of chemotherapy-induced nausea and vomiting. It reveals the potential of netupitant/palonosetron as a more effective and convenient approach to preventing this challenging side effect. The journey through cancer treatment can be tough, but research continues to offer new and innovative solutions to alleviate the burden of side effects and improve patient outcomes.
Date :
- Date Completed 2021-12-27
- Date Revised 2021-12-27
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.